期刊文献+

^125I粒子不同分布组织间植入对荷人胃癌裸鼠移植瘤疗效的影响 被引量:11

Impact of different dose distribution of ^125I seeds interstitial brachytherapy on the effects in human gastric carcinoma bearing nude mice
原文传递
导出
摘要 目的探讨^125I粒子总活度相同时,不同分布的组织间植入对荷人胃癌裸鼠移植瘤疗效的影响。方法建立人胃低分化腺癌BGC-823细胞裸鼠皮下移植瘤模型32只,按随机数字表法分为实验组和对照组。实验组植入总活度33.30MBq ^125I粒子,按照植入单枚活度及分布不同分为高活度组(33.30MBq×1枚)、中活度组(16.65MBq×2枚)、低活度组(11.10MBq×3枚);对照组植入空源粒子。每组8只裸鼠模型。比较实验和对照组及^125I粒子不同分布状态下对移植瘤体积的抑制率、组织病理学改变、局部皮肤反应、裸鼠体质量和存活率。采用方差分析和秩和检验对数据进行统计学处理。结果各组存活率均为100%。^125I粒子植入第30天裸鼠体质量各组比较,差异无统计学意义[高、中、低活度及对照组分别为(26.44±1.07)、(26.58±0.51)、(27.15±1.37)和(26.92±0.60)g,F=2.23,P〉0.05]。第30天各实验组^125I粒子对肿瘤体积抑制率分别为92.47%,97.15%和89.01%;平均体积各实验组[高、中、低活度组分别为(138.85±16.45)、(52.52±30.54)、(202.72±126.97)mm^3]与对照组[(1843.99±447.63)mm^3]比较,差异均有统计学意义(t值分别为3.092,3.376,3.269,P均〈0.05),中活度组和低活度组组间比较差异有统计学意义(t:2.308,P〈0.05),高活度组分别和中活度组、低活度组组间比较差异均无统计学意义(t值分别为1.300,1.007,P均〉0.05)。高活度组与中活度组组织病理学分级按直肠癌消退分级标准(RCRG)均为RCRG1级;低活度组3只为RCRG3级,4只为RCRG2级,1只为RCRG1级。中、低活度组均未出现放射性损伤,高活度组中4只裸鼠于^125I粒子植入后9~12d出现放射治疗肿瘤学组织(RTOG)1~2级放射性损伤。结论^125I粒子植入治疗中单源活度的选择和分布方式可直接影响疗效和放射性损伤的程度。 Objective 125I seeds interstitiaI brachytherapy has been clinically used for years. However, how the dose distribution affects the therapeutic response remains to be elucidated. The present study was undertaken to investigate the impact of different dose distribution on the effects of ^125I seeds interstitial brachytherapy. Methods Thirty-two human gastric carcinoma bearing nude mice were randomly divided into three treated groups and one control group with eight mice in each group. ^125I seeds were implanted in the treated groups with the same total activity (33.30 MBq). Based on the dose distribution and activity of single seed, the treated groups were classified to high activity group (33.30 MBq × 1 ) , moderate activity group (16.65 MBq × 2 ) and low activity group (11.10 MBq × 3 ). The control group was implanted radioactivity-free seeds. The evaluation parameters were obtained after 30 d, which included survival rate, body weight, volume inhibitory rate, histological tumor regression and regional skin reaction. Analysis of variance and Kruskal-Wallis H test were used for data statistical analysis. Results All mice survived during the observation period. There was no significant difference of the body weight among the groups after ^125I seeds im- plantation (F = 2. 23, P 〉 0.05 ). The volume inhibitory rates in high, moderate and low activity groups were 92. 47% , 97. 15% and 89. 01% , respectively. After treatment the average tumor volume was (138.85 ± 16.45) mm^3 in high activity group, (52.52 ±30.54) mm^3 in moderate activity group, (202.72±126.97) mm^3 in low activity group and (1843.99 ± 447.63 )mm^3 in control group. In all treated groups, the average tumor volume was significantly smaller than that in control group (t = 3. 092, 3. 376, 3. 269, all P 〈 0.05 ). However, among the treated groups, statistically significant difference in average tumor volume was only found between moderate activity group and low activity group ( t = 2. 308, P 〈 0.05 ). The pathological complete response rectal cancer regression grade (RCRG) assessment revealed that RCRG 1 was seen in all the tumors in high activity group and moderate activity group, while all tumors showed RCRG 3 response(H = 23. 50, P 〈 0.005 ) in the control group. In low activity group 1/8 tumor was with RCRG 1, 4/8 with RCRG 2 and 3/8 with RCRG 3. Skin radiation injury was found only in 4/8 nude mice in high ac- tivity group with radiation therapy oncology group (RTOG) grade 1 - 2. Conclusion The activity of single ^125I seed and the dose distribution may exert critical impact on the therapeutic effects and radiation injury in ^125I seeds interstitial brachytherapy.
出处 《中华核医学杂志》 CAS CSCD 北大核心 2008年第5期313-316,共4页 Chinese Journal of Nuclear Medicine
基金 基金项目:河北省科学技术研究与发展计划项目(06276102D-78)
关键词 胃肿瘤 近距离放射疗法 碘放射性同位素 小鼠 Stomach neoplasms Brachytherapy Iodine radioisotopes Mice, nude
  • 相关文献

参考文献6

  • 1Pommier P, Villers A, Bataillard A, et al. Standards, options,and recommendations for brachytherapy in patients with prostate cancer: efficacy and toxicity. Cancer Radiother, 2001, 5 : 770- 786.
  • 2Ragde H, Grado GL, Nadir BS. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol, 2001, 54: 739-747.
  • 3Wheeler JM, Warren BF, Mortensen NJ, et al. Quantification of histologic regression of rectal cancer after irradiation : a proposal for a modified staging system. Dis Colon Rectum, 2002, 45: 1051- 1056.
  • 4Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer(EORTC). Int J Radiat Oncol Biol Phys, 1995, 31: 1341-1346.
  • 5Reniers B, Verhaegen F, Vynckier S. The radial dose function of low-energy brachytherapy seeds in different solid phantoms: comparison between calculations with the EGSnrc and MCNP4C Monte Carlo codes and measurements. Phys Med Biol, 2004, 49: 1569- 1582.
  • 6田志远,左书耀,王叙馥,王国明,张勤.^(125)Ⅰ粒子组织间植入对小鼠移植性肝细胞癌的治疗作用[J].中华核医学杂志,2006,26(3):174-176. 被引量:2

二级参考文献11

  • 1赵恩民,肖水芳,秦永,王全桂,郭敏,王荣福.^(125)I放射性密封源永久性置入治疗5例晚期头颈癌疗效观察[J].临床耳鼻咽喉科杂志,2004,18(6):348-349. 被引量:6
  • 2马海涛,吴翼伟,秦涌,何靖康,李忠诚.姑息性切除加术中^(125)I种子源植入治疗晚期非小细胞肺癌[J].中华核医学杂志,2003,23(6):342-343. 被引量:14
  • 3Hrabar D.Therapy of malignant liver tumors.Acta Med Croatica,2003,57:241-248.
  • 4Vucina J,Han R.Use of radionuclides in therapy.Med Pregl,2001,54:245-250.
  • 5De Werd LA,Huq MS,Das IJ,et al.Procedures for establishing and maintaining consistent air-kerma strength standards for low-energy,photon-emitting brachytherapy sources:recommendations of the Calibration Laboratory Accreditation Subcommittee of the American Association of Physicists in Medicine.Med Phys,2004,31:675-681.
  • 6Reniers B,Verhaegen F,Vynckier S.The radial dose function of lowenergy brachytherapy seeds in different solid phantoms:comparison between calculations with the EGSnrc and MCNP4C Monte Carlo codes and measurements.Phys Med Biol,2004,49:1569-1582.
  • 7Kirov AS,Williamson JF.Monte carlo-aided dosimetry of the source tech medical model STM1251 125I interstitial brachytherapy source.Med Phys,2001,28:764-772.
  • 8Merrick GS,Wallner KE,Butler WM.Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland.J Urol,2003,169:1643-1652.
  • 9Lee W,Daly BD,DiPetrillo TA,et al.Limited resection for nonsmall cell lung cancer:observed local control with implantation of 125I brachytherapy seeds.Ann Thorac Surg,2003,75:237-242.
  • 10程宝兴,吴浩荣,吴锦昌.碘-125组织间植入治疗大鼠移植性肝癌的实验研究[J].苏州大学学报(医学版),2002,22(1):13-16. 被引量:11

共引文献1

同被引文献95

引证文献11

二级引证文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部